282 related articles for article (PubMed ID: 26252081)
41. Downregulation of miR‑486‑5p in papillary thyroid carcinoma tissue: A study based on microarray and miRNA sequencing.
Wen DY; Pan DH; Lin P; Mo QY; Wei YP; Luo YH; Chen G; He Y; Chen JQ; Yang H
Mol Med Rep; 2018 Sep; 18(3):2631-2642. PubMed ID: 30015845
[TBL] [Abstract][Full Text] [Related]
42. In Situ Hybridization Analysis of miR-146b-5p and miR-21 in Thyroid Nodules: Diagnostic Implications.
Guo Z; Hardin H; Montemayor-Garcia C; Asioli S; Righi A; Maletta F; Sapino A; Lloyd RV
Endocr Pathol; 2015 May; 26(2):157-63. PubMed ID: 25771986
[TBL] [Abstract][Full Text] [Related]
43. Mapping the Molecular Basis and Markers of Papillary Thyroid Carcinoma Progression and Metastasis Using Global Transcriptome and microRNA Profiling.
Akyay OZ; Gov E; Kenar H; Arga KY; Selek A; Tarkun İ; Canturk Z; Cetinarslan B; Gurbuz Y; Sahin B
OMICS; 2020 Mar; 24(3):148-159. PubMed ID: 32073999
[TBL] [Abstract][Full Text] [Related]
44. An Ep-ICD based index is a marker of aggressiveness and poor prognosis in thyroid carcinoma.
He HC; Kashat L; Kak I; Kunavisarut T; Gundelach R; Kim D; So AK; MacMillan C; Freeman JL; Ralhan R; Walfish PG
PLoS One; 2012; 7(9):e42893. PubMed ID: 23049733
[TBL] [Abstract][Full Text] [Related]
45. Genome-Wide Expression Screening Discloses Long Noncoding RNAs Involved in Thyroid Carcinogenesis.
Liyanarachchi S; Li W; Yan P; Bundschuh R; Brock P; Senter L; Ringel MD; de la Chapelle A; He H
J Clin Endocrinol Metab; 2016 Nov; 101(11):4005-4013. PubMed ID: 27459529
[TBL] [Abstract][Full Text] [Related]
46. Integrated analyses of microRNA and mRNA expression profiles in aggressive papillary thyroid carcinoma.
Yang Z; Yuan Z; Fan Y; Deng X; Zheng Q
Mol Med Rep; 2013 Nov; 8(5):1353-8. PubMed ID: 24064622
[TBL] [Abstract][Full Text] [Related]
47. MicroRNA signature predicts survival in papillary thyroid carcinoma.
Chengfeng X; Gengming C; Junjia Z; Yunxia L
J Cell Biochem; 2019 Oct; 120(10):17050-17058. PubMed ID: 31099134
[TBL] [Abstract][Full Text] [Related]
48. MicroRNA-mediated networks underlie immune response regulation in papillary thyroid carcinoma.
Huang CT; Oyang YJ; Huang HC; Juan HF
Sci Rep; 2014 Sep; 4():6495. PubMed ID: 25263162
[TBL] [Abstract][Full Text] [Related]
49. Combination of serum microRNAs and ultrasound profile as predictive biomarkers of diagnosis and prognosis for papillary thyroid microcarcinoma.
Zhang Y; Pan J; Xu D; Yang Z; Sun J; Sun L; Wu Y; Qiao H
Oncol Rep; 2018 Dec; 40(6):3611-3624. PubMed ID: 30542708
[TBL] [Abstract][Full Text] [Related]
50. Downregulation of long noncoding RNA NONHSAT037832 in papillary thyroid carcinoma and its clinical significance.
Lan X; Sun W; Zhang P; He L; Dong W; Wang Z; Liu S; Zhang H
Tumour Biol; 2016 May; 37(5):6117-23. PubMed ID: 26611646
[TBL] [Abstract][Full Text] [Related]
51. Down-regulation of 14q32-encoded miRNAs and tumor suppressor role for miR-654-3p in papillary thyroid cancer.
Geraldo MV; Nakaya HI; Kimura ET
Oncotarget; 2017 Feb; 8(6):9597-9607. PubMed ID: 28030816
[TBL] [Abstract][Full Text] [Related]
52. Loss of DNA methylation is related to increased expression of miR-21 and miR-146b in papillary thyroid carcinoma.
Ortiz IMDP; Barros-Filho MC; Dos Reis MB; Beltrami CM; Marchi FA; Kuasne H; do Canto LM; de Mello JBH; Abildgaard C; Pinto CAL; Kowalski LP; Rogatto SR
Clin Epigenetics; 2018 Nov; 10(1):144. PubMed ID: 30454026
[TBL] [Abstract][Full Text] [Related]
53. Exosomal miRNAs are potential diagnostic biomarkers between malignant and benign thyroid nodules based on next-generation sequencing.
Pan Q; Zhao J; Li M; Liu X; Xu Y; Li W; Wu S; Su Z
Carcinogenesis; 2020 Mar; 41(1):18-24. PubMed ID: 31560760
[TBL] [Abstract][Full Text] [Related]
54. miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma.
Minna E; Romeo P; Dugo M; De Cecco L; Todoerti K; Pilotti S; Perrone F; Seregni E; Agnelli L; Neri A; Greco A; Borrello MG
Oncotarget; 2016 Mar; 7(11):12731-47. PubMed ID: 26871295
[TBL] [Abstract][Full Text] [Related]
55. miR-183 regulates biological behavior in papillary thyroid carcinoma by targeting the programmed cell death 4.
Wei C; Song H; Sun X; Li D; Song J; Hua K; Fang L
Oncol Rep; 2015 Jul; 34(1):211-20. PubMed ID: 26063221
[TBL] [Abstract][Full Text] [Related]
56. MiR-221, a potential prognostic biomarker for recurrence in papillary thyroid cancer.
Dai L; Wang Y; Chen L; Zheng J; Li J; Wu X
World J Surg Oncol; 2017 Jan; 15(1):11. PubMed ID: 28061868
[TBL] [Abstract][Full Text] [Related]
57. A three-microRNA panel in serum as novel biomarker for papillary thyroid carcinoma diagnosis.
Zou X; Gao F; Wang ZY; Zhang H; Liu QX; Jiang L; Zhou X; Zhu W
Chin Med J (Engl); 2020 Nov; 133(21):2543-2551. PubMed ID: 33009019
[TBL] [Abstract][Full Text] [Related]
58. MiRNA-146b-5p upregulates migration and invasion of different Papillary Thyroid Carcinoma cells.
Lima CR; Geraldo MV; Fuziwara CS; Kimura ET; Santos MF
BMC Cancer; 2016 Feb; 16():108. PubMed ID: 26883911
[TBL] [Abstract][Full Text] [Related]
59. Clinical pathological impacts of microRNAs in papillary thyroid carcinoma: A crucial review.
Chruścik A; Lam AK
Exp Mol Pathol; 2015 Dec; 99(3):393-8. PubMed ID: 26321247
[TBL] [Abstract][Full Text] [Related]
60. Dynamic monitoring of circulating microRNAs as a predictive biomarker for the diagnosis and recurrence of papillary thyroid carcinoma.
Zhang Y; Xu D; Pan J; Yang Z; Chen M; Han J; Zhang S; Sun L; Qiao H
Oncol Lett; 2017 Jun; 13(6):4252-4266. PubMed ID: 28599426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
